Sri Sri Tattva gets approval for herbal drug for mild to moderate COVID-19 therapy

All the ingredients of the herbal drug NAOQ19 are selected by thorough literature review

The Interdisciplinary Technical Review Committee (ITRC) of the Ministry of AYUSH, Government of India, has approved Bengaluru-based Sri Sri Tattva’s NAOQ19 as an add-on therapy for mild to moderate COVID-19 infection after reviewing the double-blind, randomized controlled trials conducted at some of the prestigious institutes like AIIMS Jodhpur, AIIMS Rishikesh and GIMS Noida.

NAOQ19 is a polyherbal formulation with a blend of 13 powerful herbs and their extracts which helps to enhance and strengthen the immune system. It also helps in conditions like fever, cold & cough, respiratory disorders and inflammatory conditions.

Sri Sri Tattva had partnered with Sri Sri Institute of Advanced Research (SSIAR) to conduct pilot trials on the efficacy of NAOQ19, along with standard of care, in treating mild to moderate COVID-19 infection. The first pre-clinical studies (In vitro and In vivo studies) were conducted at Foundation of Neglected Diseases and Research (FNDR), Bengaluru. The results were very encouraging which prompted them to conduct clinical trials on a larger scale with some of the most renowned institutes of the country. These findings were then presented to The Interdisciplinary Technical Review Committee (ITRC), which is setup by Ministry of AYUSH to review and approve the drug trials on COVID-19 patients.

image credit- shutterstock

Read Previous

EssEmm Corp unveils Cosmos Nut Butter Grinder, First-of-its-kind in India

Read Next

Yakult Danone India inks strategic MoU with NIFTEM, Kundli 

Leave a Reply